Telisotuzumab adizutecan

N/A

Report date: 2026/05/26 15:01:49

Base Information

Drug NameTelisotuzumab adizutecan
Drug Alias NameTemab-AABBV-400
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionHepatocyte growth factor receptor inhibitorsDNA topoisomerase I inhibitors
TargetsHepatocyte growth factor receptorDNA topoisomerase I
Therapy Area/IndicationsEsophageal adenocarcinomaGastroesophageal Junction NeoplasmsSolid tumours +[15] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[23] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesAbbvie IncAbbvie Pharmaceutical Trading（Shanghai）Co Ltd
Inactive CompaniesN/A
Active IndicationsEsophageal adenocarcinomaGastroesophageal Junction NeoplasmsSolid tumours +[15] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A